Dr. Chaft on Ongoing Pivotal Trials in EGFR-Mutant NSCLC

Jamie E. Chaft, MD
Published Online: Wednesday, Apr 19, 2017



Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

The most anticipated trial is the FLAURA study, which is exploring first-line osimertinib (Tagrisso) versus erlotinib (Tarceva) and gefitinib (Iressa) in patients with EGFR T790M-mutant NSCLC, Chaft explains.

However, the one caveat is that the trial’s primary endpoint is progression-free survival, and researchers question whether osimertinib will demonstrate an overall survival advantage. Furthermore, it is unclear whether they should utilize a first- or second-generation drug after osimertinib or if there will be new drugs available that are specifically targeted at the time of progression on osimertinib.
 


Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

The most anticipated trial is the FLAURA study, which is exploring first-line osimertinib (Tagrisso) versus erlotinib (Tarceva) and gefitinib (Iressa) in patients with EGFR T790M-mutant NSCLC, Chaft explains.

However, the one caveat is that the trial’s primary endpoint is progression-free survival, and researchers question whether osimertinib will demonstrate an overall survival advantage. Furthermore, it is unclear whether they should utilize a first- or second-generation drug after osimertinib or if there will be new drugs available that are specifically targeted at the time of progression on osimertinib.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Redefining Treatment Paradigms in the Management of Chronic Lymphocytic LeukemiaOct 05, 20172.0
Community Practice Connections: 15th Annual International Congress on the Future of Breast Cancer®Oct 06, 20172.0
Publication Bottom Border
Border Publication